Invitrogen™ Romosozumab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA541957	100 μg

Catalog No. PIMA541957

Supplier: Invitrogen™ MA541957

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoporosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7, 8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9, 2019.

Specifications

• Antigen: Romosozumab Humanized
• Applications: ELISA, SDS-Page
• Classification: Recombinant Monoclonal
• Concentration: 2 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: 785A070802; AMG 785; CDP-7851; romosozumab-aqqg; sclerostin Ab
• Host Species: Human
• Immunogen: Human SOST.
• Purification Method: Protein A/G
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG2 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov